A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Semisynthetic broad-spectrum cephalosporin.
One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in soil, fecal matter, and sewage. It is an opportunistic pathogen and causes cystitis and pyelonephritis.
Benzoate derivatives that contain one or more alkyl or aryl groups linked to the benzene ring structure by OXYGEN.
A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Naturally occurring family of beta-lactam cephalosporin-type antibiotics having a 7-methoxy group and possessing marked resistance to the action of beta-lactamases from gram-positive and gram-negative organisms.
Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
A cephalosporin antibiotic.
A group of glycine amides of aminobenzoic acids.
A hexosyltransferase involved in the transfer of disaccharide molecules to the peptidoglycan structure of the CELL WALL SKELETON. It plays an important role in the genesis of the bacterial CELL WALL.
A semisynthetic cephamycin antibiotic resistant to beta-lactamase.

Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. (1/55)

It is not known whether a prophylactic antibiotic administered prior to surgery reaches adequate levels in the peritoneum, where peritonitis may take place. This study determined levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. Fifteen patients who underwent elective gastrointestinal surgery received an intravenous drip infusion of cefmenoxime (2 g) over 1 h prior to surgery. In patients who underwent gastrectomy, the level of cefmenoxime in serum was 130.8 +/- 6.9 micrograms/ml at laparatomy and decreased to 5.0 +/- 0.7 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues at laparotomy were 35.3 +/- 5.2 and 19.2 +/- 3.5 micrograms, respectively, and decreased time dependently. In patients who underwent cholecystectomy, the level of cefmenoxime in serum was 137.9 +/- 7.3 micrograms/ml at laparotomy and decreased to 5.0 +/- 1.2 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues were 31.0 +/- 8.4 and 13.7 +/- 3.3 micrograms/g, respectively, and decreased time dependently. The level of cefmenoxime in serum correlated with the levels of cefmenoxime in parietal peritoneum (r = 0.64, P less than 0.01) and in omentum (r = 0.47, P less than 0.02). In patients with appendicitis who received a bolus injection of 2 g of cefmenoxime, the level of drug in inflammatory omental tissue correlated with the level in serum. The levels in peritoneal tissue during surgery lasting up to 2 h were significantly greater than in MIC of cefmenoxime against almost all bacteria reported. A preoperative single dose of 2 g of cefmenoxime probably is effective as a prophylactic for intraoperative contamination.  (+info)

Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. (2/55)

We investigated the synergistic effects of romurtide (MDP-Lys [L18]) and cefmenoxime (CMX) in the treatment of experimental Klebsiella pneumonia in mice. Mice were infected with 1 x 10(4) CFU of Klebsiella pneumoniae by inhalation of aerosol bacterial suspension. About 90% of untreated animals died within a week; however, the mortality rate of animals treated with CMX alone at a dose of 40 mg/kg/day was 60% at 7 days after the infection. When one or two doses of L18 were administered before or after the infection concomitantly with CMX, a remarkable improvement in the survival rate was observed. There was no significant improvement in the survival rate of animals treated with L18 alone before or after infection. Histopathological sections of the lungs of mice treated with CMX and L18 showed slower progression of infection than those of mice treated with CMX alone. Significant differences were also found in quantitative cultures of viable bacteria in the lungs 1 to 4 days after the infection. Although viable bacterial counts in the lungs of the control and CMX-treated groups showed a rapid increase 24 to 48 h after the infection, they remained lower than the initial counts (x 10(4)) in the lungs of mice treated with combination regimens. From these results, it can be concluded that L18 is a useful biological response modifier in the treatment of acute pulmonary bacterial infections.  (+info)

Studies on condensed-heterocyclic azolium cephalosporins. III. Synthesis and antibacterial activity of 7 beta-[2-(2-amino-5-substituted-thiazol-4-yl)-2 (Z)-alkoxyiminoacetamido]-3-(condensed-heterocyclic azolium)methyl-3-cephem-4- carboxylates. (3/55)

As a part of our research on the synthesis of cephalosporins bearing condensed-heterocyclic azolium groups at the 3 position in the cephalosporin nucleus, we describe herein the synthesis of 7 beta-[2-(2-amino-5-halogeno-, methylthio-, methylsulfinyl-, methylsulfonyl- and sulfothiazol-4-yl)-2(Z)-alkoxyiminoacetamido] cephalosporins and their antibacterial activity. Among the compounds prepared, 7 beta-[2-(2-amino-5-chlorothiazol-4-yl)-2(Z)- methoxyiminoacetamido]-3-(imidazo[1,5-a]-pyridinium-1-yl)methyl-3-cephem -4-carboxylate (14) showed good antibacterial activity against both Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, whereas the antibacterial activity against other Gram-negative bacteria was a slightly lower than that of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-(im ida zo [1,2-a]pyridinium (I-1) and imidazo[1,5-a]pyridinium (I-4)-1-yl)methyl-3-cephem-4-carboxylates.  (+info)

Application of mathematical model to multiple-dose experimental chemotherapy for fatal murine pneumonia. (4/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered for 7 days to mice with pneumonia caused by Klebsiella pneumoniae by using dosage regimens that would simulate multiple dosing in usual clinical treatments at dosing intervals of 8 or 12 h. Viable numbers of the bacteria in the lungs were measured at 12- or 24-h intervals. The mathematical model established in a previous single-dose study was applied in this study to explain the time courses of the changes in bacterial count over 7 days. However, because the error in viable count measurements was larger than that in the previous study, the time course of the changes in mean viable count was not regular and the viable count reduction rate changed during multiple dosing, and therefore it was difficult to explain the time course by repeated application of the mathematical model described previously. This study suggests that the changes in pharmacokinetic and pharmacodynamic parameters during multiple dosing need to be considered.  (+info)

Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in mice. (5/55)

In previous papers (Y. Ikeda and T. Nishino, Antimicrob. Agents Chemother. 32:1073-1077, 1988; Y. Ikeda, T. Nishino, and T. Tanino, Antimicrob. Agents Chemother. 31:865-869, 1987), we reported that many of the 7-aminothiazolyl cephalosporins, such as cefmenoxime, showed paradoxically reduced activity against Proteus vulgaris at higher concentrations, whereas these paradoxical effects were not observed for other types of cephalosporins, such as cefbuperazone and cefoperazone. In this study, we compare the therapeutic effect of cefmenoxime with that of cefbuperazone and explore the in vivo paradoxical effect of cefmenoxime by using an experimental infection model in mice. In an intraperitoneal infection with P. vulgaris 11, the survival rate with cefmenoxime was increased to 43% at 3.13 mg/kg but was lower at higher doses. On the other hand, cefbuperazone did not show such a paradoxical therapeutic effect. In mice infected with P. vulgaris 11, cefmenoxime levels in both serum and peritoneal washings were rapidly reduced and beta-lactamase activities in the peritoneal cavity were increased at higher cefmenoxime doses. These findings suggested that high levels of cefmenoxime at the infection site induced increased production of beta-lactamase, which then rapidly inactivated the antibiotic. We conclude that the paradoxical therapeutic effect of cefmenoxime against P. vulgaris occurs by the same mechanisms as the in vitro effect and that the high beta-lactamase inducibility and low beta-lactamase stability may account for the paradoxical therapeutic effect of cefmenoxime against P. vulgaris.  (+info)

Application of mathematical model to experimental chemotherapy of fatal murine pneumonia. (6/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered in an experimental model of murine pneumonia caused by Klebsiella pneumoniae in a way which enabled us to approximate the serum antibiotic concentration time course in humans. Bacterial counts during the experiments were subjected to nonlinear least-squares analyses by using a mathematical model that explained the bacterial killing by the antibiotic concentration time course and other factors associated with antimicrobial potency and bacterial growth. Cefazolin gave a killing curve that changed synchronously with the drug levels in serum; in contrast, cefmenoxime gave a curve that was prolonged as compared with the change in the drug levels in serum. Multiple correlation coefficients were about 0.9, and the model worked well for bacterial count data. Parameters relating to antimicrobial potency of the drugs, bacterial growth rate, and drug distribution into the tissue were estimated numerically.  (+info)

In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. (7/55)

To determine the cytotoxicity of antibiotic eyedrops to ocular surface cells using a semi-quantitative method, a range of commercially available antibiotic eyedrops were assessed by using three corneal cell lines and one conjunctival cell line. All antibiotic solutions were free of benzalkonium chloride. Cell viability was determined by the MTT assay and neutral red assay following the exposure of cells to the undiluted, 2- and 10-fold diluted drugs for 10, 30, and 60 min. Toxicity was compared using % cell viability score (%CVS) . The tested eyedrops and values of %CVS50 and %CVS40/80 were Bestron((R)) (cefmenoxime, 100, 94) , Panimycin((R)) (dibekacin, 86, 58) , Noflo((R)) (norfloxacin, 90, 50) , Cravit((R)) (levofloxacin, 86, 46) , Tosfulo((R)) (tosufloxacin, 57, -3) , and Vigamox((R)) (moxifloxacin, 57, -6) . Cell viability markedly increased after dilution. For instance, cell viability assayed by MTT was > 80% for all the measurements in antibiotics diluted 10-fold, and the rate of the measurements showing > 80% cell viability decreased to 43% (31 out of 72 measurements) in the solutions diluted 2-fold. Of the drugs tested, Bestron((R)) containing cefmenoxime showed the weakest toxicity. Vigamox((R)) containing moxifloxacin and Tosuflo((R)) containing tosufloxacin were more toxic when compared with the other antibiotics. CVS was useful for the comparison of the cytotoxicity of the drugs.  (+info)

Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester. (8/55)

BMY-28271, the acetoxyethyl ester of BMY-28232, 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3(Z) -propen-1-yl-3- cephem-4-carboxylic acid, is a new oral cephalosporin. BMY-28232 has a widely expanded spectrum with high activity against gram-positive and gram-negative bacteria. BMY-28232 is far more active than cefixime or cefteram against Staphylococcus aureus and Staphylococcus epidermidis. Against gram-negative bacteria, the activity of BMY-28232 was comparable to or somewhat weaker than that of cefixime or cefteram. BMY-28232 was a poor substrate for various beta-lactamases. Orally administered BMY-28271 had a good therapeutic effect on systemic infections with S. aureus and some gram-negative bacteria in mice. Oral BMY-28271 was efficacious against S. aureus Smith infection: the efficacy of BMY-28271 was 80 to 90 times higher than that of cefixime or cefteram.  (+info)

[Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].: One percent cefmenoxime (CMX) ototopical solution was administered to 302 pa
Cefmenoxime is a medicine available in a number of countries worldwide. A list of US medications equivalent to Cefmenoxime is available on the Drugs.com website.
Product Number , 78097775. CAS Number , 75738-58-8. EC , Molecular Formula , C16H18ClN9O5S3. Molecular Weight , 548.02. Storage Temp , Harmonized Tariff code , 29419000. Signal Word , ...
TY - JOUR. T1 - Autocrine human growth hormone promotes invasive and cancer stem cell-like behavior of hepatocellular carcinoma cells by STAT3 dependent inhibition of CLAUDIN-1 expression. AU - Chen, Yi Jun. AU - You, Ming Liang. AU - Chong, Qing Yun. AU - Pandey, Vijay. AU - Zhuang, Qiu Shi. AU - Liu, Dong Xu. AU - Ma, Lan. AU - Zhu, Tao. AU - Lobie, Peter E.. N1 - Funding Information: This work was funded by The key research and development program of China (2016YFC1302305), The National Natural Science Foundation of China (81672615, 81472494, and 81272925) and The Cancer Science Institute through grants from The Ministry of Education, Singapore and National Research Foundation, Singapore and by grants from the National Medical Research Council of Singapore (R-713-000-163-511) and (R-713-000-206-511). Peter E. Lobie was also supported by The Chinese Academy of Sciences President?s International Fellowship Initiative (PIFI) Grant No. 2015VBA031. Publisher Copyright: © 2017 by the authors. ...
Clinivex is a high quality reference standard supplier of 2-(2-Aminothiazol-4-yl)acetic Acid-13C,15N2 Hydrochloride, CAS no - . View more information regarding 2-(2-Aminothiazol-4-yl)acetic Acid-13C,15N2 Hydrochloride, including solubility, MSDS & more.
1LSP: Structure of a bulgecin-inhibited g-type lysozyme from the egg white of the Australian black swan. A comparison of the binding of bulgecin to three muramidases.
In Japan, Neisseria gonorrhoeae, a sexually transmitted pathogen, has recently shown significant resistance to various antimicrobial agents. In this study, a checkerboard method was utilized to investigate the in vitro activities of cefixime (CFIX), cefteram (CFTM), or amoxicillin (AMPC) in combinat …
Synthesis and structure-activity relationships of 7.BETA.-[2-(2-aminothiazol-4-yl)acetamido]-cephalosporin derivatives. III. Synthesis and antibacterial activity of 7.BETA.-[2-amino-2-(2-aminothiazol-4-yl)acetamido]cephalosporins.:III. SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 7β-[2-AMINO- 2-(2-A MINOTHIAZOL-4-YL)ACETAMIDO]CEPHALOSPORINS (1980 ...
A new broad-spectrum generation wormer for pigs that can be administered through drinking water has been launched at the Pig and Poultry Fair 2012.
Special Instructions apply for IS3, IS4 and IS6 to maintain the environmental rating of Type 3R for these parts. Instructions are located on the enclosure door. Drip shield is required on IS3, drip shield is recommended on IS4 and IS6. Drain holes are required on all. ...
We,China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Suppliers and China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Manufacturers, provide 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 product and the products related with China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 - Otsuka Chemical
Doctors give trusted answers on uses, effects, side-effects, and cautions: Dr. Khairullah on nitrofurantoin side effects: Outside of allergic reactions, which are not unique to cefdinir, none of the cephalosporins have side-effects which are very significant. They include cases of gastrointestinal discomfort with nausea, vomiting and diarrhea and rash as occasional occurrences. Sold as omnicef, it is one of several oral cephalosporins.
InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/ ...
an oral cephalosporin (trade names Keflex and Keflin and Keftab) commonly prescribe for mild to moderately severe infections of the skin or ears or throat or lungs or urinary tract. ...
... is a third-generation cephalosporin antibiotic. Diseases Database (DDB): 30892 Yokota N, Koguchi M, Suzuki Y, ... Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262-6. doi:10.1159/ ... Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial ... Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime ...
These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be ...
The first products TAP file new drug applications for, were two cephalosporins, cefmenoxime (Cefmax) and cefsulodin (Cefonomil ...
Cefmax cefmenoxime (INN) cefmepidium chloride (INN) cefmetazole (INN) cefminox (INN) Cefobid cefodizime (INN) cefonicid (INN) ...
... s such as metronidazole, tinidazole, cephamandole, latamoxef, cefoperazone, cefmenoxime, and furazolidone, cause a ...
... cefmenoxime MeSH D02.065.589.099.249.190.190.135 - cefotiam MeSH D02.065.589.099.249.190.190.145 - ceftizoxime MeSH D02.065. ...
... cefmenoxime, cefmetazole, cefonicid, cefoperazone, cefotetan, ceftriaxone, and latamoxef (moxalactam); thought to be due to ...
Examples of such sodium salts are (selection): Bispyribac, bithionol, bosentan, brequinar, bromfenac, Cefmenoxime, ceftiofur, ...
J01DC14 Flomoxef J01DD01 Cefotaxime J01DD02 Ceftazidime J01DD03 Cefsulodin J01DD04 Ceftriaxone J01DD05 Cefmenoxime J01DD06 ...
... cefmenoxime 1983 - ceftazidime 1983 - ceftizoxime 1983 - norfloxacin 1984 - cefonicid 1984 - cefotetan 1984 - temocillin 1985 ...
"Cefmenoxime" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Cefmenoxime" by people in this website by year, and whether " ... Below are the most recent publications written about "Cefmenoxime" by people in Profiles. ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime, ETP, IMP, SCF, LVX. Recovered. KPC-2, SHV, TEM, CTX-M-15 ...
Other antibiotics that may interact with alcohol include tinidazole, ketoconazole, furazolidon, cefmenoxime, cefoperazone, and ...
Cefmenoxime Hydrochloride. Cefmenoxime Hydrochloride (2:1). Hydrochloride, Cefmenoxime. SCE 1365. SCE-1365. SCE1365. ... Cefmenoxime - Preferred Concept UI. M0023523. Scope note. A cephalosporin antibiotic that is administered intravenously or ... cefmenoxime Scope note:. Antibiótico cefalosporínico de administración intravenosa o intramuscular. Es activo frente a la ... Cefmenoxime Hydrochloride - Narrower Concept UI. M0023525. Preferred term. Cefmenoxime Hydrochloride Entry term(s). Cefmenoxime ...
Cefmenoxime Susc Islt Code System Concept Status. Published. Code System Preferred Concept Name. Cefmenoxime [Susceptibility]. ...
InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1 ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Cefmenoxime D2.886.675.966.500.249.190.190.125 D2.886.665.74.190.190.125. D4.75.80.875.99.221.249.190.190.125. Cefmetazole ...
Okonogi K., Kuno M., Kida M., Mitsuhashi S. 1981a; β-Lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), ...
Cefotaxime and cefmenoxime showed next most potent activities with MIC80s of 0.06 µg/ml. The antimicrobial activity of ... Cefotaxime and cefmenoxime showed next most potent activities with MIC80s of 0.06 µg/ml. The antimicrobial activity of ... Cefotaxime and cefmenoxime showed next most potent activities with MIC80s of 0.06 µg/ml. The antimicrobial activity of ... Cefotaxime and cefmenoxime showed next most potent activities with MIC80s of 0.06 µg/ml. The antimicrobial activity of ...
However, BMY-28142, cefbuperazone, cefmenoxime, cefotaxime, ceftizoxime, and moxalactam were equivalent in activity and rate of ... were compared with those of cefmenoxime, cefoperazone, cefotaxime, ceftizoxime, and moxalactam. BMY-28142 was the most active ...
Cefmenoxime, Cefoperazone, Cefotiam, Cefoxitin, Ceftriaxone, Ciprofloxacin, Enoxacin, Erythromycin, Moxalactam, Ofloxacin, ...
ebook mastering fermentation recipes for making and cooking with respond to soak your photoinduced cefmenoxime. It gets ...
CEFMENOXIME HEMICHLORHYDRATE *CEFOTETAN DISODIQUE *CEFOXITINE SODIQUE *CEFPODOXIME PROXETIL *CEFTAZIDIME *CEFTIZOXIME SODIQUE * ...
Cefprozil Cephalexin Cefpodoxime Cephalothin Cefatrizine Cephradine Cefditoren Cephaloglycin Ceftizoxime Loracarbef Cefmenoxime ...
Cefmenoxime. 1389. Enterococci. 32. >32. ? - ?. Cephalothin (Cefalotin, Keflin, Seffin). 1389. Enterococci. 32. -. ? - ?. ...
  • Cefuzonam, cefmenoxime, cefozopran and cefotaxime among the cephems showed excellent antimicrobial activities against S. pneumoniae. (elsevier.com)
  • Cefotaxime and cefmenoxime showed next most potent activities with MIC 80 s of 0.06 µg/ml. (elsevier.com)
  • Cefmenoxime" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uchicago.edu)
  • β -Lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin. (microbiologyresearch.org)
  • Cefmenoxime hydrochloride The procedure strategy was transformed in 89.2% situations of positive Family pet/CT scans which ultimately shows us that 18F-FDG Family pet/CT imaging ought Cefmenoxime hydrochloride to be built-into the follow-up applications for DTC sufferers. (eprf.ca)
  • In our research, the entire Cefmenoxime hydrochloride instances of intense variations such as for example insular, diffuse sclerosing variations of papillary or follicular Hurthle cell carcinoma was uncommon, and that's the Cefmenoxime hydrochloride reason only a genuine amount of 5 individual were referred for exterior rays beam and TKI therapy. (eprf.ca)